Evidence map›Paper›PMID 32637582›Full record

ArticleMolecular therapy oncolytics2020

miR-7 Reduces Breast Cancer Stem Cell Metastasis via Inhibiting RELA to Decrease ESAM Expression.

Miao Li, Meng Pan, Jing Wang, Chengzhong You, Fengshu Zhao, Danfeng Zheng, Mei Guo, Hui Xu, Di Wu, Ling Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Downregulation of miR‑7 and miR‑153 is involved inInternational journal of oncology · 2023
    Article
  9. Review
  10. Targeting Breast Cancer Stem Cells.International journal of biological sciences · 2023
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. MiR-7 in Cancer Development.Biomedicines · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Miao LiDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Meng PanDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Jing WangDepartment of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Chengzhong YouDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Fengshu ZhaoDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Danfeng ZhengDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Mei GuoDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Hui XuDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Di WuDepartment of Gynecology & Obstetrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Ling WangDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Jun DouDepartment of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing 210009, China.
Southeast University · CNZhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to present evidence that miR-7 inhibited the metastasis of breast cancer stem cells (BCSCs) and elucidated the mechanisms that have remained unknown. The samples collected from miR-7 agomir-treated, BCSC-driven tumors were subjected to a protein array to analyze the protein expression profiles. A dual-luciferase reporter and chromatin immunoprecipitation-PCR were used to validate and evaluate the molecular expressions of interest in the collected breast cancer tissues and cell lines. miR-7 overexpression affecting metastasis of BCSCs was further evaluated in mice. The endothelial cell-selective adhesion molecule (ESAM) was highly expressed in breast cancer tissues and in BCSC-driven xenografts. Results of the dual-luciferase reporter and chromatin immunoprecipitation-PCR indicated that the miR-7 mimic reduced RELA expression by directly targeting the 3' UTR of RELA to inhibit ESAM expression in MDA-MB-231 cells. Moreover, the expression levels of RELA, CD44, and ESAM were significantly decreased in lentivirus (Lenti)-miR-7-BCSC-driven xenografts compared with the control xenografts, accompanied with an increase in E-cadherin and a decrease in vimentin expression, as well as reduction in tumor growth and metastasis to lungs. Our data demonstrated that miR-7 overexpression reduced the metastasis of BCSCs via inhibiting ESAM, suggesting that ESAM could be a potential target for breast cancer therapy.

Indexed as

breast cancerbreast cancer stem cellsendothelial cell-selective adhesion moleculeendothelial cell-selective adhesion molecule(ESAM)metastasismiR-7

Identifiers

PMID32637582
PMCPMC7327889
OpenAlexW3034056662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.